VALITOR, INC.
Protein-polymer therapeutics conjugating anti-TNFα antibodies to hyaluronic acid for intravitreal injection to treat uveitis
- Sector
- Biotech
- Headquarters
- Moraga, CA
- Founded
- 2018
- Latest Form D
- $8.4M, Jan 2022
- Total capital
- $13.1M
- Federal grants
- $3M
- 10 awards · 2015–2021
- Rank in peer group#338 of 514
- Private capital raised
- $10.2M
- 2 Form D · last Jan 2022
- 57 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 2
- 27 pending · first 2026
- Rank in peer group#142 of 514
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 2nd filing$8.4M
- Federal grantHealth and Human S · Phase I · Antibody-hyaluronic acid bioconjugates for localized treatment of chronic non-infectious uveitis$299K
- Private capital raisedForm D · SEC · 1st filing$1.7M
- Federal grantHealth and Human S · Phase I · Bifunctional Protein-Polymer Bioconjugates for Localized Melanoma Immunotherapy$299K
- Federal grantHealth and Human S · Phase I · Anti-inflammatory bioconjugates for sustained inhibition of post-traumatic osteoarthritis following joint injury$225K
- Federal grantHealth and Human S · Phase I · Long acting anti TNFα conjugates to minimize osteolysis around joint replacement devices$225K
- Federal grantHealth and Human S · Phase I · Long-acting anti-TNFα conjugates to minimize osteolysis around joint replacement devices$225K
Show 5 earlier federal awards
- Federal grantHealth and Human S · Phase I · Multivalent Anti-VEGF Conjugates for Sustained Treatment of Diabetic Retinopathy$32K
- Federal grantHealth and Human S · Phase I · Multivalent Anti VEGF Conjugates for Sustained Treatment of Diabetic Retinopathy$318K
- Federal grantHealth and Human S · Phase I · Multivalent Anti-VEGF Conjugates for Sustained Treatment of Diabetic Retinopathy$286K
- Federal grantHealth and Human S · Phase I · Multivalent protein-polymer conjugates to improve growth factor stability and therapeutic efficacy for wound healing$285K
- Federal grantHealth and Human S · Phase II · Multivalent Conjugates of Sonic Hedgehog to Accelerate Diabetic Wound Healing$783K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
41months
from VALITOR, INC.’s first federal award to its first private round.
- First federal award · Apr 2015
- Health and Human S · $783K
- First Form D · Sep 2018
- $1.7M · 1st Form D
- Awards before first raise
- 9 awards
An association in public records, not a cause or a prediction.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grantsBelow median
- Granted patents#142 · top 28%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Jackson M WesleyResearcherExecutive Officer, DirectorLinked by 1 patent · $1.7M in grants as PI
- Wesley M. JacksonResearcherExecutive Officer, DirectorLinked by 1 patent · $1.7M in grants as PI
- Anthony M. AiudiDirectorNamed in SEC Form D filings
- Carole H BellisExecutive OfficerNamed in SEC Form D filings
- Drew M LanzaDirectorNamed in SEC Form D filings
- Gail E. MaderisDirectorNamed in SEC Form D filings
Show all 9 people
- Kevin E HealyDirectorNamed in SEC Form D filings
- Manish M. KothariDirectorNamed in SEC Form D filings
- Walter M. MoosDirectorNamed in SEC Form D filings
What it has protected
USPTO · 2 granted of 29- GrantedHYDROPHILIC LINKERS FOR ANTIBODY OR DARPin CONJUGATESUSPTOUS 12,729,236
- GrantedMultivalent Peptide Conjugates For Sustained Intra-articular Treatment Of Joint InflammationUSPTOUS 12,599,663
- PendingMethod Of Treating Uveitis With Multivalent Protein-hyaluronic Acid Polymer ConjugateUSPTOApplication 18856982
Show all 29 patent records
- HYDROPHILIC LINKERS FOR ANTIBODY OR DARPin CONJUGATESSep 8, 2026 · US 12,729,236Granted
- Multivalent Peptide Conjugates For Sustained Intra-articular Treatment Of Joint InflammationApr 14, 2026 · US 12,599,663Granted
- Method Of Treating Uveitis With Multivalent Protein-hyaluronic Acid Polymer ConjugateAug 14, 2025 · Application 18856982Pending
- Method Of Treating A Cancer With A Multivalent Peptide ConjugateJul 3, 2025 · Application 18848753Pending
- Purified Multivalent Protein-hyaluronic Acid Polymer ConjugatesDec 21, 2023 · Application 18300831Pending
- Humanized Multivalent Protein ConjugatesDec 21, 2023 · Application 18300823Pending
- HYDROPHILIC LINKERS FOR ANTIBODY OR DARPin CONJUGATESAug 11, 2022 · Application 17622467Pending
- Multivalent Aptamer-polymer ConjugatesApplication PCTUS2024051750Pending
- Purified Multivalent Protein-hyaluronic Acid Polymer ConjugatesApplication PCTUS2023065777Pending
- Humanized Multivalent Protein ConjugatesApplication PCTUS2023065778Pending
- Method Of Treating Uveitis With Multivalent Protein-hyaluronic Acid Polymer ConjugateApplication PCTUS2023065779Pending
- Method Of Treating A Cancer With A Multivalent Peptide ConjugateApplication PCTUS2023064741Pending
- Method of Treating Uveitis with Multivalent Protein-Hyaluronic Acid Polymer ConjugateApplication 63331554Pending
- Humanized Multivalent Protein ConjugatesApplication 63331534Pending
- Purified Multivalent Protein-hyaluronic Acid Polymer ConjugatesApplication 63331548Pending
- Method Of Treating A Cancer With A Multivalent Peptide ConjugateApplication 63321971Pending
- Hyrophilic Linkers For Multivalent Peptide ConjugatesApplication PCTUS2020040430Pending
- Hydrophilic Linkers For Peptide-polymer ConjugatesApplication 62898967Pending
- Hyrophilic Linkers For Multivalent Peptide ConjugatesApplication 62869233Pending
- Multivalent Peptide Conjugates For Sustained Intra-articular Treatment Of Joint InflammationApplication PCTUS2019021460Pending
- Multivalent Peptide Conjugates For Sustained Intra-articular Treatment Of Joint InflammationApplication 62640749Pending
- Multivalent Aptamer-polymer ConjugatesApplication 63591343Pending
- Multivalent Aptamer-polymer ConjugatesApplication 19527534Pending
- Multivalent Protein ConjugatesApplication PCTUS2025056053Pending
- Multivalent Protein ConjugatesApplication 63899734Pending
- Multivalent Protein ConjugatesApplication 63874443Pending
- Multivalent Protein ConjugatesApplication 63818964Pending
- Multivalent Protein ConjugatesApplication 63800041Pending
- Multivalent Protein ConjugatesApplication 63722904Pending
Related companies, and why
- TELLUS THERAPEUTICS INCSimilar federal contract value in Biotech · null in contracts
- IBEX BIOSCIENCES, LLCSimilar federal contract value in Biotech · null in contracts
- RESONANT THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
- ETIRARX, INC.Similar federal contract value in Biotech · null in contracts
- Lila Biologics, Inc.Similar federal contract value in Biotech · null in contracts
- PLEIOGENIX INC.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .